Q-omics provides the consensus-scored TFAP2A profile across patient tissues and cancer cell-line models. TFAP2A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TFAP2A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TFAP2A RNA expression shows 17,446 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where TFAP2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFAP2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFAP2A survival associations across molecular data types. TFAP2A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFAP2A RNA expression–survival associations across cancer types. High TFAP2A expression shows unfavorable associations in KIRP, KIRC, LUAD, THCA and LIHC, but favorable associations in UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TFAP2A RNA expression.
This table summarizes TFAP2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TFAP2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFAP2A shows lower tumor expression in KIRC and higher tumor expression in HNSC, COAD, LUAD, LUSC and STAD. The KIRC box plot shows higher TFAP2A RNA expression in normal versus tumor tissue (log2 FC = −2.411, t-test p < 0.001).
This table shows molecular features associated with TFAP2A in patient tissues and cancer cell lines. In patient samples, TFAP2A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TFAP2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
